Fish oil medicine to lower heart risk in heart disease patients
Part of Heart & circulation clinical trials.
This study tests whether a purified fish oil medicine called icosapent ethyl (IPE), taken along with your usual statin, can further lower the risk of heart attacks and strokes in people who already have heart or blood vessel disease. It aims to reduce the leftover risk even after standard cholesterol treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 45 years or older.
- You must have been diagnosed with heart or blood vessel disease (like a heart attack, stroke, or blocked arteries).
- You must be taking a stable dose of a statin (cholesterol-lowering medicine) for at least 4 weeks.
- Your recent blood tests must show: triglycerides between 150 and 500 mg/dL, LDL (bad) cholesterol between 40 and 100 mg/dL, and HDL (good) cholesterol between 30 and 50 mg/dL.
- If you are a woman who can become pregnant, you must not be pregnant, plan to become pregnant, or be breastfeeding, and you must use an acceptable birth control method.
- You must not have severe heart failure, severe liver disease, or a history of pancreatitis, and you must not be allergic to fish or shellfish.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a prescription fish-oil medicine called icosapent ethyl can improve heart health by reducing plaques (fatty deposits) in the arteries, lowering inflammation, and helping the heart remodel (recover) after a heart event. It is designed for people with heart disease and high triglycerides.
This study looks at how omega-3 fatty acids (healthy fats found in fish oil) are carried in your blood. You will take a fish oil supplement and have blood tests to see how your body processes these fats.
This study tests whether combining a low-dose statin with ezetimibe is safe and effective for people who have very early signs of plaque buildup in their arteries but are not yet at high risk. The goal is to see if this combination can prevent heart disease from getting worse.
This study tests whether a purified omega-3 fatty acid called icosapent ethyl can reduce inflammation and shrink high-risk plaques in your heart arteries. It uses a special PET/CT scan to see if the medicine helps stabilize these plaques over time.
This study tests whether a special diet can reduce inflammation and improve heart health in people over 55 who are at increased risk for heart disease but have not yet had a heart attack or stroke.
This study tests whether two types of omega-3s (EPA and DHA) help improve HDL (good cholesterol) and reduce blood clot risk in people with high triglycerides and low HDL cholesterol.
Hear when a new Atherosclerosis Cardiovascular Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.